VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. - Test2 - elhamkhani - TriplyDB

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.

http://www.wikidata.org/entity/Q35064894

about

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications New immunotherapies targeting the PD-1 pathway Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy PD-1 and its ligands are important immune checkpoints in cancer Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.Immunotherapeutic approaches for hepatocellular carcinoma Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma.Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.PD-1(+) and Foxp3(+) T cell reduction correlates with survival of HCC patients after sorafenib therapy TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies.The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment.Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib.PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma.Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects.Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.Angiogenic factors and inflammation in steroid-refractory acute graft-vs-host disease.Immunotherapy in Sarcoma: Future Horizons.PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.Immunological landscape and immunotherapy of hepatocellular carcinoma.Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.New agents on the horizon in gastric cancer.Vaccines for established cancer: overcoming the challenges posed by immune evasion.Vaccine-based immunotherapeutic approaches to gliomas and beyond.Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy.Reversing T-cell Dysfunction and Exhaustion in Cancer.Chemotherapy for advanced gastric cancer: future perspective in Japan.The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?Endothelial epsins as regulators and potential therapeutic targets of tumor angiogenesis.Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study Vessel pruning or healing: endothelial metabolism as a novel target?Sunitinib in kidney cancer: 10 years of experience and development.Strategies to overcome therapeutic resistance in renal cell carcinoma.Barriers to Radiation-Induced In Situ Tumor Vaccination.

P2860

Q26996518-8806985A-6EBF-4A35-B988-AF6F75F10B50 Q27010018-DEB72E99-2E4E-4D08-A052-D54D5DB69673 Q28066199-0DDCC968-7D30-423F-A822-838785491D6C Q28069485-21628E39-5908-497A-AE0B-A05FB224A145 Q28553961-8F8789D2-15F9-41AA-8D3C-7E68C7391D65 Q30275254-C2304BD8-BC32-478F-958C-D00357D3BD44 Q33779723-0FF84A37-F79F-41C4-B99C-696D90677619 Q36344920-D2A4DA03-23AB-4963-8D10-D2A644CB8DAE Q36535465-BB77233E-E8D6-49FB-9466-2B4412A93B92 Q36777149-57203215-2206-4DDD-AEE5-15E7CE42DCA3 Q37057942-14CECC93-E495-4493-8530-0A42AD6F3BD0 Q37079133-A607D890-C283-4FC9-BD14-7A26DB3D075D Q37079141-49ADF235-CD1D-4D4A-9D47-F72BBFE7A0FF Q37179971-9B945C05-87CD-44D2-BA37-356746FCF6A6 Q37277182-F95B1A17-F10A-4AB0-9571-2F19E588F107 Q37516448-E9326C04-A724-4591-AB1F-32F34C9660C9 Q37687194-34E0CE19-80E7-4357-BEE6-48F9CEFD7568 Q37687323-0AC73610-CAC4-4A94-A964-920AD9688289 Q37725613-11C5237E-8D44-4884-8EF5-D35CA2F06AEB Q38413904-12BF8565-24B5-4431-99E7-5F33D195EF6E Q38514440-923AF066-27CD-472B-9A01-D3C1E4DE5F62 Q38539063-C8D618A6-1365-485D-A726-B1B170FF814C Q38596093-56109718-7F96-4C5E-B958-1802A1F64ACD Q38607549-6558C458-440A-4159-858C-2D7FD96FF80E Q38611895-FE346035-44EE-4266-9678-6DBA74B24245 Q38728953-00B24A1E-0FD3-44B0-9823-0C57C9867E12 Q38759129-F1CE1025-3101-4471-88E2-98774651AE38 Q38769021-C4B8B8E7-9972-4C15-9366-2DB236439139 Q38789860-94228B2D-B5FA-4BAD-872E-A244AB328DFF Q38795278-A809BEA3-A85A-49F9-80EE-4B690EB8A7C2 Q38809776-7C493862-AB34-4DCB-A3CD-C766B808B5E6 Q38815071-8D2CBCFB-56A5-4562-8DD7-BA55102AB881 Q38831655-44D03726-05C0-488E-AA4F-B7A607E5C63C Q38835601-2C6CB551-D8D7-4B41-9549-56EB71BDECD5 Q38939975-0CB62192-88C8-4EF1-84E0-EAF9DFFE1A08 Q38979882-8C6AE756-F328-431B-B720-FA3B8CC5019A Q39024164-AFB8F334-37EF-4E2A-B6D2-F0D04EB0B345 Q39038214-FB7842D4-4337-4442-B388-C8D3EC22F2D1 Q39089402-E8454755-B6DB-4BF7-8FD6-E5532692FBB4 Q39203685-2ACE4D60-3350-4E5D-8230-806DADF35A4B

P2860

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.

http://www.wikidata.org/entity/Q35064894

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.

@ast

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.

@en

type

label

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.

@ast

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.

@en

prefLabel

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.

@ast

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.

@en

P1433

Q35064894-ABDDD937-6BD3-4566-AFB0-CF1622036089

P1476

Q35064894-20816DCF-05F3-4B5B-82FB-4C981165CE8A

P2093

Q35064894-0776954D-3B67-4C42-9549-77E0A3A1F836

Q35064894-1309D7F7-8CD9-418A-9431-2B9DC9CD75A4

Q35064894-268D8AD1-BC96-437A-973A-18895B9BFE8A

Q35064894-2BDD8819-768F-48A2-ABFD-D484A737B4B4

Q35064894-471581C3-B105-4952-A1F2-1A87F693B404

Q35064894-57C801A6-E410-4988-B469-AC40F7767F36

Q35064894-582C7209-9B34-417D-8D54-784688EA5B4C

Q35064894-593B628E-2E27-4EAA-B74C-95E7C8834284

Q35064894-59F241C5-5774-4E95-A8DE-7B890A0CA1F2

Q35064894-5ABE0AFA-2705-478F-86A7-91D62AF02BAE

P2860

Q35064894-0504E481-B87C-4257-BB77-403DA6994315

Q35064894-07BCAE75-F336-4825-A97F-89E257401A1B

Q35064894-21D44777-40AA-49D0-8247-C1D63C675D54

Q35064894-2BD3150A-7B3B-4932-8044-4C8DC066793D

Q35064894-3098E5FD-90E1-4723-B29B-D165F5CDFC39

Q35064894-330B41B3-49A9-454F-90D8-6A728141CA98

Q35064894-442EE729-D315-4501-8276-356236415ECD

Q35064894-5964F5BB-2015-4E01-AFF3-B343C1406ABE

Q35064894-59BEF7DE-A4A6-4990-88C1-4577B8DA3AB7

Q35064894-62DD503C-603B-4172-B526-88267E3CAD58

P304

Q35064894-E23DF3E7-3413-4A84-8C46-91583FDABD64

P31

Q35064894-469567CD-C5A3-40D2-BF84-594E2FE08CDE

P356

Q35064894-05A953E1-52F3-407F-9700-DC0BAE6D17B1

P407

Q35064894-C9FC8C04-30D3-465B-85F8-2C21D9B523E9

P433

Q35064894-85D3A0E7-EAE4-4193-A9D9-51265511E910

P478

Q35064894-F287CF86-D719-4DFE-8A17-FA8083949207

P50

Q35064894-0280FD60-B8EE-4550-B6A7-53CC511446BC

Q35064894-03B07774-DDA3-4212-B22C-A0234ABF0005

Q35064894-9D36ED43-8C1D-448B-9028-199E2659E531

P577

Q35064894-F5B81FE2-27FC-44D9-B464-D3A2D19293EB

P5875

Q35064894-DED8A630-5003-4D18-897A-56B446D32B6D

P698

Q35064894-A8605001-B606-4832-ADFF-9D20971A0622

P932

Q35064894-E19CE50D-B98F-4C94-8BE4-8C3D303EBD52

P356

P1433

Journal of Experimental Medicine

P1476

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.

@en

P2093

Anne Berger

http://www.w3.org/2001/XMLSchema#string

Anne-Laure Pointet

http://www.w3.org/2001/XMLSchema#string

Christian Stockmann

http://www.w3.org/2001/XMLSchema#string

Corinne Tanchot

http://www.w3.org/2001/XMLSchema#string

Elie Marcheteau

http://www.w3.org/2001/XMLSchema#string

Franck Zinzindohoue

http://www.w3.org/2001/XMLSchema#string

Hideo Yagita

http://www.w3.org/2001/XMLSchema#string

Mevyn Nizard

http://www.w3.org/2001/XMLSchema#string

Nadine Benhamouda

http://www.w3.org/2001/XMLSchema#string

Orianne Colussi

http://www.w3.org/2001/XMLSchema#string

P2860

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis

Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

T cell exhaustion

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

NFATc1 regulates PD-1 expression upon T cell activation.

P304

139-148

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20140559

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

212

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

271334154

http://www.w3.org/2001/XMLSchema#string

P698

25601652

http://www.w3.org/2001/XMLSchema#string

P932

4322048

http://www.w3.org/2001/XMLSchema#string